Frédéric Bertaïna

Bioxis Pharmaceuticals

Frédéric Bertaïna is the CEO of Bioxis Pharmaceuticals, a French Medical Device startup focusing on biopolymers for their use in cosmetic surgery.
Over the last 5 years, Frédéric raised over 10M€, launched his company’s first product (generated 2M€ sales on the first semester after launch) and plans are in place to start a new phase 1 clinical trial in Q1 2020 for the revolutionary technology MTI12.
Frédéric graduated with an MSc in Strategy and Healthcare Management from ESSEC business school, in Project Management & Geopolitics from University of Paris Est and followed several trainings in Pharmaceutical Development at Kings College London.